Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Open Access
- 1 August 2014
- journal article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 36 (8), 1130-1146
- https://doi.org/10.1016/j.clinthera.2014.06.008
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trialsDiabetes & Metabolism, 2012
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*Diabetes, Obesity and Metabolism, 2011
- The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2011
- Pharmacokinetics of dipeptidylpeptidase‐4 inhibitorsDiabetes, Obesity and Metabolism, 2010
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in HumansPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2009
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patientsDiabetes, Obesity and Metabolism, 2009
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 2008
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 InhibitorsJournal of Pharmacology and Experimental Therapeutics, 2008